2nd Quarter - Report

KOUNTOUPES DENHAM CARR & REID, LLC for GLENMARK PHARMACEUTICALS, INC., USA

Firm
Client
Income
$50,000
Expenses
—

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

General information about the company and the industry. Issues related to affordability and pricing of pharmaceuticals.

Foreign entity interest: Glenmark Pharmaceuticals Inc. USA (GPI) is the North American division of Glenmark Pharmaceuticals, Ltd. (GPL), a corporation formed under the laws of India. GPL, as GPIs upstream foreign parent, has an interest in the listed issues.

LobbyistCovered position, as disclosed
LISA KOUNTOUPES —
DAVID PAUL PELUSO —
MARY R "RANDI" REID —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Health Issues HCR

General education about the generic pharmaceutical industry.

Foreign entity interest: Glenmark Pharmaceuticals Inc. USA (GPI) is the North American division of Glenmark Pharmaceuticals, Ltd. (GPL), a corporation formed under the laws of India. GPL, as GPIs upstream foreign parent, has an interest in the listed issues.

LobbyistCovered position, as disclosed
LISA KOUNTOUPES —
DAVID PAUL PELUSO —
MARY R "RANDI" REID Legislative Director, Legislative Assistant and Projects Director, Legislative Assistant - Senator Michael Enzi (R-WY); Legislative Director - Rep. Michael Burgess (R-TX)

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Medicare/Medicaid MMM

Issues related to Medicaid CPI Penalty.

Foreign entity interest: Glenmark Pharmaceuticals Inc. USA (GPI) is the North American division of Glenmark Pharmaceuticals, Ltd. (GPL), a corporation formed under the laws of India. GPL, as GPIs upstream foreign parent, has an interest in the listed issues.

LobbyistCovered position, as disclosed
LISA KOUNTOUPES —
DAVID PAUL PELUSO —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Copyright/Patent/Trademark CPT

Issues related to the abuses of the patent system, extensions of drug exclusivity, pay-for-delay, and the inter partes review (IPR) process, including H. R. 1499, the Protecting Consumer Access to Generic Drugs Ace of 2019, and H. R. 938, the BLOCKING Act of 2019.

Foreign entity interest: Glenmark Pharmaceuticals Inc. USA (GPI) is the North American division of Glenmark Pharmaceuticals, Ltd. (GPL), a corporation formed under the laws of India. GPL, as GPIs upstream foreign parent, has an interest in the listed issues.

LobbyistCovered position, as disclosed
LISA KOUNTOUPES —
DAVID PAUL PELUSO —
MARY R "RANDI" REID —
ROSE SULLIVAN (LISTED IN ERROR) —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1499 (116th), H.R. 938 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.